PHARMASSET INC (NASDAQ: VRUS)





$22.78 0.50 (2.26%)
Real-time 12:00:00 AM ET
Turn On
KEY STATS
52-Week High Price
24.60
52-Week Low Price
7.62
Avg Volume (3 Mo.)
0.00 M
Market Cap
0.62 B
P/E Ratio (TTM)
0.0
Diluted EPS (TTM)
-1.59
Shares
28.28 M
Dividend Rate ($) / (%)
0.00/0.00
100%
0%
You need to upgrade your Flash Player to view the graph.
View by Date Range:
12 Mo. Price Change : 88% - VRUS has outperformed the S&P 500 by 62%
SIMILAR COMPANIES
NameCurrent Price - Today's ChangeMarket Cap
MARTEK BIOSCIENCES CORP (MATK) $20.37 -  $0.37(1.85%)0.67 B
VIVUS INC (VVUS) $8.46 -  $0.22(2.67%)0.67 B
MOMENTA PHARMACEUTICALS (MNTA) $14.62 -  $0.01(0.03%)0.65 B
AMAG PHARMACEUTICALS INC (AMAG) $36.06 -  $0.61(1.68%)0.65 B
EVOTEC AKTIENGESELLSCH... (EVTCY) $5.06 -  $0.06(1.20%)0.62 B
CELL THERAPEUTICS INC (CTIC) $0.77 -  $0.13(19.56%)0.61 B
XENOPORT INC (XNPT) $18.97 -  $0.15(0.78%)0.58 B
MICROMET INC (MITI) $8.14 -  $0.02(0.25%)0.57 B
SYNERGY PHARMACEUTICALS (SGYP) $6.40 -  $0.00(0.00%)0.56 B
TARGACEPT INC (TRGT) $20.58 -  $0.27(1.33%)0.56 B
STOCK ANALYSIS
Stock Analysis
Five Must-Ask Questions Before Taking The IPO Bait
IPOs often make great discussion but lousy investments. Learn how to avoid getting burned.
VRUS RELATED HEADLINES
arrow
Stocks Showing Unusually Heavy Volume - Titanium Metals Corp, Pharmasset Inc, Cell Genesys Inc
Here are the results for today's unusual stock volume scan. The scan looks at the previous day's volume and compares it to the recent average volume...(Read More)

By SchaeffersResearch 4/21/2009
arrow
INTERVIEW-Vertex out-foxes big pharma to acquire ViroChem
VERTEX/ (INTERVIEW):INTERVIEW-Vertex out-foxes big pharma to acquire ViroChem

Forbes.com 3/4/2009
arrow
Build your Biotech Basket
<ul> <li>Lazard Capital Markets 5th Annual Healthcare Conference</li> <li>Meridian's Test and Treat program</li> <li>A non invasive prenatal diagnostic treatment</li> <li>MAP Pharmaceuticals has new pediatric asthma treatment</li> </ul>

Wall Street Media 11/18/2008
arrow
Top Biotech Stocks
<ul> <li>Novavax has planned trial for flu vaccine in 2009</li> <li>Spectrum in Phase III trials</li> <li>Momenta works on treatment for MS</li> </ul>

Wall Street Media 11/13/2008
Stock Simulator- Free Account
Chart Advisor- Free Report
Sponsored Links
COLOSIM2